Beijing Innocare Pharma Tech Co. Ltd. has patented molecular glue degrader compounds acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers reported to be useful for the treatment of cancer, autoimmune diseases, inflammation, neurodegenerative and dermatological disorders.

China Resources Pharmaceutical Research Institute (Shenzhen) Co. Ltd. has prepared and tested Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.

Cytosinlab Therapeutics Co. Ltd. has synthesized G/T mismatch-specific thymine DNA glycosylase (TDG) inhibitors reported to be useful for the treatment of cancer.

Zenyaku Kogyo Co. Ltd. has identified myosin light chain kinase family member 4 (MYLK4; SGK085) inhibitors reported to be useful for the treatment of arteriosclerosis, inflammatory bowel disease, osteosarcoma, glaucoma, ocular hypertension, dry eye, uveitis and age-related macular degeneration, among others.

Dewpoint Therapeutics Inc. has described TAR DNA-binding protein 43 (TARDBP; TDP-43) modulators reported to be useful for the treatment of traumatic brain injury, frontotemporal dementia and amyotrophic lateral sclerosis.

Work at Erciyes University has led to the discovery of antimicrobial peptides with potential for the treatment of bacterial and fungal infections.

Jacobio Pharmaceuticals Co. Ltd. has reported new fused tetracyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors potentially useful for the treatment of cancer.

Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have synthesized new mast/stem cell growth factor receptor kit (KIT; c-KIT; CD117) inhibitors reported to be useful for the treatment of urticaria.

Janssen Pharmaceutica NV has identified new compounds reported to be useful for the treatment of SARS-CoV-2 infections (COVID-19).

Albireo Ltd. has patented new benzothia(di)azepine compounds acting as ileal sodium/bile acid cotransporter (SLC10A2; IBAT; ASBT) and/or sodium-bile acid cotransporter (SLC10A1; NTCP) inhibitors reported to be useful for the treatment of diabetes, cardiovascular, gastrointestinal, liver and renal disorders.